XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Sees Large Decrease in Short Interest

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 9,750 shares, a decline of 49.3% from the May 14th total of 19,218 shares. Based on an average daily trading volume, of 26,934 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Down 9.0%

XTL Biopharmaceuticals stock opened at $2.13 on Friday. The stock has a 50-day simple moving average of $2.54 and a 200 day simple moving average of $4.48. XTL Biopharmaceuticals has a 12-month low of $2.01 and a 12-month high of $10.28. The stock has a market capitalization of $4.69 million, a price-to-earnings ratio of -3.33 and a beta of 1.48.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.